Journal of Medical Economics
Volume 25, 2022 - Issue 1
Oncology
Cost-effectiveness analysis of KTE-X19 CAR T therapy versus real-world standard of care in patients with relapsed/refractory mantle cell lymphoma post BTKi in England
Svenja Petersohna OPEN Health, Rotterdam, The NetherlandsCorrespondence[email protected]
https://orcid.org/0000-0001-5058-7645
https://orcid.org/0000-0001-5058-7645, Gilles Sallesb Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, United Stateshttps://orcid.org/0000-0002-9541-8666
https://orcid.org/0000-0002-9541-8666, Michael Wangc Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, United Stateshttps://orcid.org/0000-0001-9748-5486
https://orcid.org/0000-0001-9748-5486, Jim Wud Kite, a Gilead Company, Santa Monica, United Stateshttps://orcid.org/0000-0003-4130-4601
https://orcid.org/0000-0003-4130-4601, Sally W. Wadee Wade Outcomes Research and Consulting, Salt Lake City, United Stateshttps://orcid.org/0000-0003-4726-7995
https://orcid.org/0000-0003-4726-7995, Claire L. Simonsf OPEN Health, York, United Kingdomhttps://orcid.org/0000-0003-0822-7261
https://orcid.org/0000-0003-0822-7261, Craig Bennisonf OPEN Health, York, United Kingdomhttps://orcid.org/0000-0001-8658-5510
https://orcid.org/0000-0001-8658-5510, Rubina Siddiqid Kite, a Gilead Company, Santa Monica, United Stateshttps://orcid.org/0000-0003-0244-1531
https://orcid.org/0000-0003-0244-1531, , , Gab Castaigneg Kite, a Gilead Company, London, United Kingdomhttps://orcid.org/0000-0001-5569-6453
https://orcid.org/0000-0001-5569-6453 & Georg Hessh Department of Hematology, Oncology and Pneumology University Medical School of the Johannes Gutenberg-University, Mainz, Germanyhttps://orcid.org/0000-0002-9282-5688
https://orcid.org/0000-0002-9282-5688 show all